nmdp logo

Haplo vs MUD An Apples to Apples Comparison and What This Could Mean for Your Patients

On-demand panel discussion link


A direct comparison between MUD and haplo graft sources when both groups receive PTCy based GvHD prophylaxis was not known. The CIBMTR® (Center for International Blood and Marrow Transplant Research®) recently published the results of this first-of-its-kind study (GS18-01 study) to answer this question looking at an "apples to apples" comparison of the outcomes of transplants for acute leukemia or myelodysplastic syndrome in adults using haplo or matched unrelated donor where both received PTCy based GVHD prophylaxis.

This session will take a deep dive into the study findings, focusing on real life application in how it relates to graft source selection and patient treatment plans.

Learning Objectives

Viewers of this session will grow their knowledge and understanding of:

  • Utilization of various stem cell donor sources in recent years and prior comparisons between haplo and MUD transplants
  • Outcomes of stem cell transplant in acute leukemia and MDS using haplo versus MUD with PTCy
  • Outcomes of stem cell transplant for NHL and HD using haplo versus MUD with PTCy

Target Audience

Physicians, medical directors


  • Mahasweta Gooptu, MD, Assistant Professor of Medicine, Harvard Medical School
  • Alberto Mussetti, MD, Director, Transplant and Cell Therapy, Institut Catalá d'Oncologia, Barcelona
  • Stephen Spellman, MBS, Vice President, Research, NMDP